Patents by Inventor Maire Doyle

Maire Doyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1, exendin-4, peptide analogs and uses thereof
    Patent number: 10941187
    Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: March 9, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
  • GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF
    Publication number: 20150072930
    Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 12, 2015
    Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
  • GLP-1, exendin-4, peptide analogs and uses thereof
    Patent number: 8853160
    Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: October 7, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
  • GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF
    Publication number: 20120329715
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 27, 2012
    Applicant: The Gov. of the US, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • GLP-1, exendin-4, peptide analogs and uses thereof
    Patent number: 8278272
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: October 2, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • GLP-1, exendin-4, peptide analogs and uses thereof
    Publication number: 20090253625
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: December 18, 2008
    Publication date: October 8, 2009
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • GLP-1 exendin-4 peptide analogs and uses thereof
    Patent number: 7576050
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: August 18, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • Glp-1 exendin-4 peptide analogs and uses thereof
    Publication number: 20040242853
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: April 1, 2004
    Publication date: December 2, 2004
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle